Lundbeck

Lundbeck challenge to EC pay-for-delay ruling fails

Lundbeck was unable justify why the agreements were needed to protect its intellectual property rights on Celexa, according to the Commission. ... Lundbeck insists it did not go beyond the protection already offered by its patent rights on Celexa.

Newron back on track for Xadago approval in US

The monoamine oxidase type B inhibitor is used as an add-on to levodopa therapy - the mainstay of Parkinson's disease treatment - and competes with Lundbeck and Teva's Azilect (rasagiline),

Surging sales of Lundbeck's CNS drugs assist recovery

Two newer antidepressants help boost sales after Cipralex patent ends. Surging sales of four new central nervous system drugs helped Denmark's Lundbeck post a 5% sales increase in the second ... Lundbeck has now raised its revenue and earnings guidance

SMC gives green light for BMS’ Opdivo

2014. Additionally, the SMC gave three further approvals to Lundbeck's antidepressant Brintellix (vortioxetine), Novartis' Cosentyx (secukinumab) for ankylosing spondylitis, and UCB's Briviact (brivaracetam) for partial-onset seizures in epilepsy

Caring for Carers

by Hill Knowlton Strategies for Otsuka Lundbeck. H K saw an opportunity for Lundbeck to address the unmet needs of family carers, looking after their loved ones who suffer from diseases ... Caring for Carers - by Hill Knowlton Strategies for Otsuka

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]